What Guerbet’s pediatric gadopiclenol label expansion reveals about the future of MRI contrast agents
FDA approval expands Guerbet’s gadopiclenol into neonates, reinforcing half-dose MRI contrast strategies. Find out what this changes for pediatric imaging.